Navigation Links
SmartCycler® 6400 System

ProductsSmartCycler® 6400 System
Company Cepheid
Item SmartCycler® 6400 System
Features 
Description The SmartCycler System is a rapid, real-time thermal cycler used for identifying DNA/RNA from prepared biological samples. By automating much of the testing process, and making each reaction site individually programmable, it is the fastest, easiest to use, and most flexible system now on the market. The SmartCycler delivers highly accurate and consistent test results in as little as 20 minutes.

Flexible
With up to 96 independently programmable reaction sites, the SmartCycler can simultaneously run multiple experiments with different protocols and at different times. This enables multiple users to use SmartCycler simultaneously. This eliminates complex advanced scheduling on larger, more costly systems as well as the need to transport samples to central facilities for analysis.

Fast
There's no need to wait hours or days for results on other platforms. With capability to perform extremely rapid heating and cooling cycles, the SmartCycler System can deliver results in as little as 20 minutes.

Real-time detection
Each independently programmable module performs four-color, real-time fluorometric detection. Samples are amplified and measured in the SmartCycler's proprietary, sealable reaction tubes that are designed to optimize rapid thermal transfer and optical sensitivity, as well as to reduce the possibility of amplicon contamination.

Four-channel optics
The SmartCycler System enables the detection of several targets within a single sample (multiplex assays) by using multiple fluorescent dyes and detecting the fluorescent signal in four channels. The instrument's optics allow application to the rapidly evolving needs of a molecular biology lab using detection methods including Molecular Beacons and TaqMan probes, Amplifluor and Scorpion primers, and intercalating dyes such as SYBR Green.

Expandable
Users can configure a system to suit their exact needs - with 16, 32, 48, 64, 80 or 96 reaction sites. As testing volumes expand, more sites can be added to a system at any time. The system software enables one or more operators to define and simultaneously carry out separate experiments, each with a unique set of cycling protocols, threshold criteria, and data analysis. Additionally, thermal and optical data can be monitored in real-time, and graphs of temperature, growth, and melt curves are displayed during data collection.

Info Cepheid
Customer Service: (408) 541-4191
Web site: http://www.cepheid.com/

Related medicine products :

1. SmartCycler® 3200 System
2. SmartCycler® 8000 System
3. Silicone Oil Cannula System - 20 Gauge
4. Silicone Oil Cannula System - 19 Gauge
5. SuperVu Galilean System
6. KOWA nonmyd 7 / VK-2 Digital Imaging System
7. KOWA nonmyd a-D / VK-2 Digital Imaging System
8. Refraction System RT-2100
9. Odyssey Phacoemulsification System
10. SIStem Phacoemulsification System
11. Precisionist Phacoemulsification System
For the quantitative determination of total cholesterol in human serum....
Intended for the quantitative determination of total cholesterol in serum. Single vial, dry powder reagent. Reaction: Endpoint. Wavelength: 500 nm. Linearity: 700 mg/dL (12.9 mmol/L)....
For the quantitative in vitro determination of lithium in serum and plasma. Wavelength: 550 nm. Linear range: up to 4 mm....
This True 12-bit integrated and cooled system is a completely self contained unit built with a long list of standard features including all-electronic-variable transilluminator and EPI lighting....
Medicine Products:
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... Feb. 8 Aton Pharma, Inc., a diversified ... has joined the company as Vice President, Commercial Operations ... A. Fishbein assumes the same role for the Ophthalmic ... LLC, Aton is focused on the development and commercialization of ...
... , , , , , ... , Feb. 8 /PRNewswire-Asia-FirstCall/ -- Renhuang,Pharmaceuticals, Inc. (Pink ... of botanical products,bio-pharmaceuticals and traditional Chinese medicines ("TCM"), announced today,that ... the fiscal year ended, October 31, 2009 on time. ...
... ... Corporation (Pinksheets: NUEC) (“NuEarth”), a manufacturer and marketer of "Clean ... Laboratory and Research Division “TerraSolv SA” has received final approval ... additional $1.3 Million laboratory service contract with the Nigerian National ...
... in the gut, triggering bone formation , MONDAY, Feb. 8 ... the gut cured osteoporosis in lab mice and rats, a ... serotonin in the gut hinders bone formation. Most current drugs ... build bone. , "New therapies that inhibit the production of ...
... divide abnormally, researchers say , MONDAY, Feb. 8 (HealthDay News) ... week may have double the risk of developing deadly pancreatic ... But the overall number of people developing the malignancy remains ... new cases last year. , "Soft drinks are linked with ...
... , WOONSOCKET, ... CVS ) today announced record revenues, operating profit, and ... ended December 31, 2009 . , (Logo: http://www.newscom.com/cgi-bin/prnh/20090226/NE75914LOGO ) ... of 2009, increased $1.7 billion to $25.8 billion , up ...
Cached Medicine News:Health News:Aton Pharma Announces Michael H. Richardson to Head Orphan Drug Division 2Health News:Renhuang Reports Record Fiscal 2009 Results; Resumes Compliance With SEC Filing Requirements 2Health News:Renhuang Reports Record Fiscal 2009 Results; Resumes Compliance With SEC Filing Requirements 3Health News:NuEarth Signs $1.3 Million Laboratory Contract 2Health News:NuEarth Signs $1.3 Million Laboratory Contract 3Health News:Drug Cures Osteoporosis in Mice 2Health News:Soft Drinks Could Boost Pancreatic Cancer Risk 2Health News:Soft Drinks Could Boost Pancreatic Cancer Risk 3Health News:Soft Drinks Could Boost Pancreatic Cancer Risk 4Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 2Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 3Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 4Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 5Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 6Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 7Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 8Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 9Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 10Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 11Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 12Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 13Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 14Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 15Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 16Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 17Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 18Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 19Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 20Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 21Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 22Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 23Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 24Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 25Health News:CVS Caremark Reports Record Results in Fourth Quarter and Fiscal 2009 26
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant ... TSX: VRX) announced that the applicable waiting period under ... respect to the previously announced tender offer by its ... of the outstanding shares of common stock of Solta ... a price of $2.92 per share, net to the ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com ... report is available in its catalogue: ... and Technologies for Advanced Drug Delivery ... Administration http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ... A drug delivery system is ...
(Date:1/15/2014)... -- A novel wearable injector slightly larger than an Oreo ... patients to self-inject prescription drugs in the large doses ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to grow to $220B by 2018, according to analysts.   ... of injector that does not exist today for self-administration ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2